Clinical Trials Logo

Anal Squamous Cell Carcinoma clinical trials

View clinical trials related to Anal Squamous Cell Carcinoma.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05130073 Completed - Clinical trials for Anal Squamous Cell Carcinoma

4-Point Therapy Response Score With PET/CT for Anal Squamous Cell Cancer

Start date: July 31, 2019
Phase:
Study type: Observational

This study determines whether a positron emission tomography (PET)/computed tomography (CT) 4-point scoring system may predict overall survival for anal squamous cell cancer patients. A 4-point scoring system involving imaging scans may help to predict how patients with anal squamous cell cancer respond to chemoradiation therapy.

NCT ID: NCT04616196 Completed - Colorectal Cancer Clinical Trials

Study of NKTR 255 in Combination With Cetuximab in Solid Tumors

Start date: October 30, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1b/2, open-label multicenter study evaluating NKTR-255 as a monotherapy and together with cetuximab in patients with head and neck squamous cell carcinoma (HNSCC), colorectal carcinoma (CRC), cutaneous squamous cell carcinoma (cSCC), anal cell carcinoma (ASCC) and cervical cancer. The recommended phase 2 dose of NKTR-255, determined in the dose escalation phase (Phase 1b), will be used to treat patients in Phase 2 of this study.

NCT ID: NCT01807546 Completed - Clinical trials for Head and Neck Squamous Cell Carcinoma

Oral Rigosertib for Squamous Cell Carcinoma

Start date: March 2013
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to determine if tumors in patients with papillomavirus (HPV) positive or negative squamous cell carcinoma (SCC) that no longer responds to standard therapy will decrease in size following treatment with the investigational drug, rigosertib sodium (ON 01910.Na). A secondary objective is to determine if treatment with rigosertib causes any side effects. Rigosertib is an investigational drug, which means that it has not been approved by the U.S. Food and Drug Administration (FDA) to treat any diseases. We are studying rigosertib as a new anticancer drug. Tests that we have done in the laboratory suggest that rigosertib works by blocking cell division in cancer cells and causing them to die.

NCT ID: NCT01285778 Completed - Clinical trials for Anal Squamous Cell Carcinoma

Vectibix for the Treatment of Anal Cancer

VITAL
Start date: October 2010
Phase: Phase 2
Study type: Interventional

Chemoradiation with 5-FU and Mitomycin C is the standard treatment in anal canal SCC. Panitumumab has shown efficacy in other tumors and anti-EGFR treatment has shown clinical activity in a single report of a refractory anal canal SCC patient. Based on this background, we propose to conduct a phase II study to investigate the efficacy and toxicity of radiotherapy with the association: - 5-FU 1000mg/m2 on days 1-4 and 29-32 - Mitomycin C 10mg/m2 on days 1 and 29 - Panitumumab 6 mg/kg on day 1, then every 2 weeks for 8 weeks

NCT ID: NCT01115790 Completed - Clinical trials for Carcinoma, Non-Small-Cell Lung

A Phase 1 Study in Participants With Advanced Cancer

Start date: February 2010
Phase: Phase 1
Study type: Interventional

The primary purpose of Parts A and B of this study is to evaluate the safety and toxicity of prexasertib (an inhibitor of checkpoint kinase 1[chk 1]) in participants with advanced or metastatic cancer (Part A), or squamous cell cancer of the head and neck or squamous cell cancer of any tumor type (Part B). Part C of the study will evaluate prexasertib in three different groups of participants; those with squamous cell cancer of the head and neck that has recurred or spread to other parts of the body, those with squamous non-small cell lung cancer that has recurred or spread, and those with squamous cell cancer of the anus that is not curable by existing therapy.